Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 Financial Results and Business Update on Thursday, November 4

Rhea-AI Summary

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) announced a conference call for November 4, 2021, at 4:30 PM ET to discuss its third-quarter financial results and provide a business update. The company specializes in developing targeted therapies for rare diseases, particularly focusing on Hepatitis Delta Virus (HDV) with treatments including Lonafarnib and peginterferon lambda, both in Phase 3 studies. Interested parties can access the live call via phone or through a webcast on Eiger's website.

Positive

• Eiger's lead programs target Hepatitis Delta Virus with two Phase 3 treatments.
• Lonafarnib and peginterferon lambda are first-in-class therapies.

Negative

• None.

PALO ALTO, Calif., Oct. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, November 4, 2021 at 4:30 PM ET to discuss its financial results and provide a business update for the third quarter 2021.

The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com.  To participate in the live call by phone, dial (844) 743-2495 (U.S.) or (661) 378-9529 (International) and enter conference ID 9874006.  The webcast will be archived and available for replay for at least 90 days after the event.

About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.

Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments.  Lonafarnib is a first-in-class, oral prenylation inhibitor and peginterferon lambda is a first-in-class, type III, well-tolerated interferon.  Both lonafarnib and peginterferon lambda are in global Phase 3 studies.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:
Sri Ryali – CFO
Email: sryali@eigerbio.com
Phone: 1-650-272-6138

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-host-conference-call-for-third-quarter-2021-financial-results-and-business-update-on-thursday-november-4-301406127.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What is the date of Eiger BioPharmaceuticals' conference call for Q3 2021 results?

The conference call is scheduled for November 4, 2021.

How can I access the conference call for EIGR's Q3 2021 results?

The call can be accessed by phone at (844) 743-2495 (U.S.) or (661) 378-9529 (International), and it will also be available via webcast on Eiger's website.

What are Eiger BioPharmaceuticals' main clinical programs?

Eiger is focused on treatments for Hepatitis Delta Virus with Lonafarnib and peginterferon lambda.

What type of company is Eiger BioPharmaceuticals?

Eiger is a commercial-stage biopharmaceutical company specializing in therapies for rare and ultra-rare diseases.